Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 9/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 6/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5722925 | 1.00 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7346709 | 1.00 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL30711484 | 1.00 | CA2 (0.55) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7145238 | 0.89 | CA2 (0.46) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4823736 | 0.89 | CA2 (0.60) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4823732 | 0.89 | CA2 (0.60) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935393 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8935402 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL10645332 | 0.86 | CA2 (0.52) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4936349 | 0.83 | CA2 (0.56) | CA2HTR1ASIGMAR1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108299364-B | A kind of synthetic method of 2- methylol chromanone | 常州大学 | 2019-07-09 | — | — | CN | claimed |
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | KANEKA CORPORATION (JP) | 2005-01-20 | — | — | US | claimed |
| CN-1564818-A | Stereoselective synthesis method of 2-hydroxymethyl-chroman | WYETH CORP (US) | 2005-01-12 | — | — | CN | claimed |
| EP-1445324-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CHROMAN DERIVATIVE AND INTERMEDIATE | KANEKA CORPORATION (JP) | 2004-08-11 | — | — | EP | claimed |
| EP-1432695-A1 | A PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 2-HYDROXYMETHYL-CHROMANS | Wyeth (US) | 2004-06-30 | — | — | EP | claimed |
| US-6700001-B2 | USEFUL AS INTERMEDIATES TO DRUGS INCLUDING THOSE TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS; STEREOSPECIFIC CYCLIZATION OF AN OPTICALLY ACTIVE PHENOL COMPOUND | WYETH | 2004-03-02 | — | — | US | claimed |
| US-20030105342-A1 | Process for stereoselective synthesis of 2-hydroxymethyl chromans | WYETH | 2003-06-05 | — | — | US | claimed |
| WO-2003031429-A1 | A PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 2-HYDROXYMETHYL-CHROMANS | WYETH (US) | 2003-04-17 | — | — | WO | claimed |
| EP-0801564-B1 | USE OF NEBIVOLOL AS AN ANTI-ATHEROGENIC | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-27 | — | — | EP | claimed |
| EP-0801564-A1 | USE OF NEBIVOLOL AS AN ANTI-ATHEROGENIC | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-10-22 | — | — | EP | claimed |
| WO-1996019987-A1 | USE OF NEBIVOLOL AS AN ANTI-ATHEROGENIC | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-07-04 | — | — | WO | claimed |
| EP-0448254-B1 | Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde | PFIZER (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0448254-A2 | Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde | PFIZER INC. (US) | 1991-09-25 | — | — | EP | claimed |
| US-4515975-A | Chroman derivatives and their preparation | BASF AKTIENGESELLSCHAFT (DE) | 1985-05-07 | — | — | US | claimed |
| EP-0052731-B1 | CHROMAN DERIVATIVES AND METHOD FOR THEIR PREPARATION | BASF Aktiengesellschaft (DE) | 1985-04-17 | — | — | EP | claimed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-4374258-A | PHOTOSTABILITY; HEAT AND OXIDATION RESISTANCE; ADDITION POLYMERS | BASF AKTIENGESELLSCHAFT (DE) | 1983-02-15 | — | — | US | disclosed |
| EP-0057425-A1 | Chromane derivatives | BASF Aktiengesellschaft (DE) | 1982-08-11 | — | — | EP | disclosed |
| EP-0052731-A1 | Chroman derivatives and method for their preparation | BASF Aktiengesellschaft (DE) | 1982-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | CA2 3892/4885HTR1A 4461/4885SIGMAR1 4496/4885 |
| US-20050014818-A1 | Process for producing optically active chroman derivative and intermediate | CYP8B1, CYP3A43, HPD | CA2 825/4885HTR1A 739/4885SIGMAR1 1763/4885 |
| US-20030105342-A1 | Process for stereoselective synthesis of 2-hydroxymethyl chromans | CYP2S1, CYP1B1, CYP1A2 | CA2 2495/4885HTR1A 57/4885SIGMAR1 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.